NIH-Funded Study at UT Austin Opens New Doors for Neuropathic Pain Treatment with MMRRC Models.

In a significant development, researchers at the University of Texas at Austin, supported by the National Institutes of Health (NIH), have identified a promising new approach to treating neuropathic pain. Highlighted by the NIH's new director, Dr. Monica M. Bertagnolli, the study utilized mice from the Mutant Mouse Resource & Research Centers (MMRRC) and the Knockout Mouse Program (KOMP) to explore innovative treatment methods.

The research focused on a specific molecule capable of binding to a protein closely involved in the mechanisms of neuropathic pain, a condition that affects millions worldwide. This binding has been shown to reduce the hypersensitivity to pain caused by nerve damage, offering a beacon of hope for those suffering from this chronic condition.

Dr. Bertagnolli emphasized the importance of this discovery, noting the critical role of NIH-funded research in advancing medical science and improving patient outcomes. The use of MMRRC mice was pivotal, demonstrating the value of these resources in facilitating high-quality research.

This breakthrough represents a vital step in developing more effective treatments for neuropathic pain, underscoring the significance of collaboration and investment in scientific research.

NIH Director Announcement:

Paper Reference:

Mouse Model Used:

View All News